Iovance Biotherapeutics develops personalized cell therapies for advanced solid tumor cancers. Its approach centers on tumor infiltrating lymphocyte (TIL) therapy, which uses a patient's own immune cells to target and attack cancer. The company's primary product, Amtagvi (lifileucel), is the first FDA-approved T cell therapy for a solid tumor indication. This one-time treatment involves extracting a patient's lymphocytes from a tumor sample, expanding them to billions of cells in a laboratory, and reinfusing them into the patient to recognize and destroy tumor cells based on unique neoantigens.
The company's technical work spans cell therapy, immunotherapy, personalized medicine, and biomanufacturing at scale. It operates a 136,000-square-foot Cell Therapy Center in Philadelphia dedicated to manufacturing. Its mission is to make TIL therapy broadly accessible, supported by a commitment to continuous innovation in the field of cell therapy.
